phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.. nav ?41.93 loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
.
.
.